Abstract
The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in comparison...
Highlights
The recent study by Hodi et al published in the Journal of Clinical Oncology has evaluated unconventional response patterns during Progressive disease (PD)-1 inhibitor therapy using immune-related response criteria in comparison with RECIST1.1, which constitutes an important step to further understand immune-related response phenomena
Tumor response criteria should serve as a “common language” to describe treatment results and provide a basis for advances in cancer therapy [2,3,4], and the detailed methods of evaluating and defining immune-related responses deserve careful review to discuss the implications of the study on further growth of immuno-oncology community
The original immune-related response criteria (irRC) used in the study by Hodi et al [1] was based on World Health Organization (WHO) criteria and utilizes bidimensional measurements, quantifying the tumor burden using a product of the longest diameter and the longest perpendicular diameter [2]
Summary
The recent study by Hodi et al published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in comparison with RECIST1.1, which constitutes an important step to further understand immune-related response phenomena. Tumor response criteria should serve as a “common language” to describe treatment results and provide a basis for advances in cancer therapy [2,3,4], and the detailed methods of evaluating and defining immune-related responses deserve careful review to discuss the implications of the study on further growth of immuno-oncology community. Response patterns unique to immune-checkpoint inhibitor therapy can be noted i) after an initial increase of tumor burden or ii) during or after the appearance of new lesions [5,6,7].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
